Metabolism

MEDITWIN Brings Together French Science and Technology Excellence Around Virtual Twins for the Future of Medical Care

Retrieved on: 
Wednesday, January 24, 2024

MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.

Key Points: 
  • MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.
  • The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment.
  • Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology.
  • The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare.

Leading Neuroscientist Daniel G. Amen, MD Launches Smart Metabolic Burn: A Breakthrough in Metabolic Wellness

Retrieved on: 
Monday, January 29, 2024

Smart Metabolic Burn is a unique 2-in-1 formula that combines clinically studied ingredients, berberine and oleoylethanolamide (OEA), in a single revolutionary formula.

Key Points: 
  • Smart Metabolic Burn is a unique 2-in-1 formula that combines clinically studied ingredients, berberine and oleoylethanolamide (OEA), in a single revolutionary formula.
  • Backed by scientific research, these ingredients have demonstrated their effectiveness in supporting metabolic wellness and healthy body composition when paired with diet and exercise.
  • Key Features of Smart Metabolic Burn:
    *Optimizes Metabolism: Smart Metabolic Burn is formulated to ignite metabolic function, helping the body efficiently convert nutrients into energy.
  • "Smart Metabolic Burn represents a significant step forward in our commitment to providing comprehensive wellness solutions.

Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

Retrieved on: 
Wednesday, January 24, 2024

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors.
  • Her industry knowledge will enable Charles River and our Board to gain powerful insights from a unique, voice-of-customer perspective and help to support our growth strategy.
  • She will complement the combined skills and experience of our current directors, and we are pleased to welcome Reshema to Charles River’s Board,” said James C. Foster, Chairman, President and Chief Executive Officer of Charles River.
  • Forward looking statements include statements in this press release regarding the specific contributions of members of Charles River's Board of Directors.

Empress Announces Formation of World Leading Scientific Advisory Board

Retrieved on: 
Tuesday, January 23, 2024

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.
  • The SAB will work closely with the leadership at Empress Therapeutics to advance the company’s Chemilogics™ platform and pipeline of drug leads.
  • “We are honored to have these extraordinary scientific leaders join Empress in its mission to generate safe, effective medicines faster and more predictably,” said Jason Park, Ph.D., Co-Founder and CEO of Empress Therapeutics.
  • “Our Scientific Advisory Board provides invaluable expertise across multiple aspects of our Chemilogics™ platform, which uses AI to discover therapeutic chemistry encoded in genetic data.

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Retrieved on: 
Tuesday, January 23, 2024

Juvena Therapeutics , a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161.

Key Points: 
  • Juvena Therapeutics , a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161.
  • JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.
  • “People living with DM1 deserve safe, effective, and rejuvenating treatments that can repair and restore tissue health to improve muscle function and metabolism,” said Dr. Hanadie Yousef, Co-Founder and CEO of Juvena Therapeutics.
  • Additionally, Juvena has identified multiple secreted protein hits that induce disease-modifying effects across several metabolic organs and therapeutic areas.

CN Bio and Altis Biosystems Partner to Develop Next-generation Human Gut/Liver in vitro model for Advanced ADME Studies

Retrieved on: 
Tuesday, January 23, 2024

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Key Points: 
  • CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.
  • CN Bio and Altis’ integrated Gut/Liver MPS bridges this gap for more accurate predictions of human drug oral bioavailability earlier in the drug development process.
  • Primary human cells are considered the gold standard for advanced in vitro models; however, gut cells present challenges that limit their use.
  • By interconnecting the RepliGut Planar-Jejunum model with CN Bio’s industry-leading primary human Liver-on-a-Chip, the dual-organ Gut/Liver model represents the next-generation of CN Bio’s oral bioavailability assay.

First-of-its-Kind Study from University of Exeter and Pvolve Researches Impact of Exercise on Women Pre and Post Menopause

Retrieved on: 
Wednesday, January 17, 2024

While women make up a large portion of the $100 billion global fitness market, they have historically been underrepresented in consumer research.

Key Points: 
  • While women make up a large portion of the $100 billion global fitness market, they have historically been underrepresented in consumer research.
  • In its Healthy Aging Study, Pvolve specifically addressed the physiological changes in aging women and the need to provide them with tailored exercise programs.
  • When engaged in a workout like Pvolve’s functional approach, the University of Exeter observed that women can experience many benefits.
  • Researchers found participants3 who consistently engaged in the Pvolve Method compared to a standard exercise routine4 noticed:
    The Healthy Aging study was conducted by the University of Exeter, which recruited 72 women aged 40-60 years old.

Pragma Bio and DayTwo Join Forces to Illuminate the Path to IBD Disease Management

Retrieved on: 
Wednesday, January 17, 2024

Pragma Bio believes that those phenotypically correlated biosynthetic pathways are the hidden path to predict and make novel clinical biomarkers and small molecules to change the landscape of IBD disease management.

Key Points: 
  • Pragma Bio believes that those phenotypically correlated biosynthetic pathways are the hidden path to predict and make novel clinical biomarkers and small molecules to change the landscape of IBD disease management.
  • Pragma Bio and DayTwo aim to identify biosynthetic pathways associated with IBD.
  • This approach overcomes many existing hurdles of drug design and optimizes for both safety and significantly improved management of disease.
  • By harnessing cutting-edge technology and comprehensive datasets, Pragma Bio and DayTwo will make groundbreaking contributions to the field of IBD research and therapeutics,” said Aamir Rehman, CEO of DayTwo.

Dream Scenario: A Staggering 78% of Americans Are Looking to Improve Their Sleep in 2024, New Survey Reveals

Retrieved on: 
Thursday, January 25, 2024

LOS ANGELES, Jan. 25, 2024 /PRNewswire/ -- How often do you get a good night's sleep? The latest study commissioned by Herbalife confirms what we may have suspected: Americans' sleep situation is far from ideal. A staggering 78% of Americans are trying to improve their sleep in 2024, with nearly half ranking this as their No. 1 priority in life right now. But what is standing in the way of Americans getting better-quality sleep?

Key Points: 
  • The latest study commissioned by Herbalife confirms what we may have suspected: Americans' sleep situation is far from ideal.
  • A staggering 78% of Americans are trying to improve their sleep in 2024, with nearly half ranking this as their No.
  • "The unfortunate truth is the blue light from TVs, phones, and digital devices unequivocally impairs sleep quality.
  • The survey also examined Americans' sleep habits and the undeniable havoc they can wreak on both sleep quality and overall health.

Research from the Korea University College of Medicine Explores the Combined Health Impact of Diabetes and Sarcopenia in the Elderly

Retrieved on: 
Wednesday, January 24, 2024

SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Diabetes mellitus and sarcopenia pose a substantial challenge to public health, especially among the elderly. These conditions share common pathophysiological mechanism and are linked bidirectionally, with each contributing to an increased risk of the other. Previous research has shown that both diabetes and sarcopenia are individually linked to serious health complications including cardiovascular conditions that may result in death. However, there is limited research on the combined health impact of diabetes and sarcopenia, particularly in vulnerable populations such as the elderly.

Key Points: 
  • Previous research has shown that both diabetes and sarcopenia are individually linked to serious health complications including cardiovascular conditions that may result in death.
  • However, there is limited research on the combined health impact of diabetes and sarcopenia, particularly in vulnerable populations such as the elderly.
  • Additionally, further research is needed to understand the intricate mechanisms linking diabetes and sarcopenia to and develop targeted treatments to enhance health outcomes."
  • Title of original paper: Additive impact of diabetes and sarcopenia on all-cause and cardiovascular mortality: A longitudinal nationwide population-based study